Blinded and unblinded internal pilot study designs for clinical trials with count data
暂无分享,去创建一个
[1] Richard Nicholas,et al. Considerations in the design of clinical trials for relapsing multiple sclerosis , 2012 .
[2] J. Wittes,et al. The role of internal pilot studies in increasing the efficiency of clinical trials. , 1990, Statistics in medicine.
[3] C Jennison,et al. Estimating the sample size for a t-test using an internal pilot. , 1999, Statistics in medicine.
[4] Heinz Schmidli,et al. Blinded sample size reestimation with count data: Methods and applications in multiple sclerosis , 2010, Statistics in medicine.
[5] Meinhard Kieser,et al. Blinded Sample Size Reestimation in Multiarmed Clinical Trials , 2000 .
[6] H Merabet,et al. The design and analysis of sequential clinical trials , 2013 .
[7] A Whitehead,et al. Mid-trial design reviews for sequential clinical trials. , 2001, Statistics in medicine.
[8] G. Wassmer,et al. Comments on the Draft Guidance on “Adaptive Design Clinical Trials for Drugs and Biologics” of the U.S. Food and Drug Administration , 2010, Journal of biopharmaceutical statistics.
[9] Ludwig Kappos,et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. , 2012, The New England journal of medicine.
[10] Draft Guidance. Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics DRAFT GUIDANCE , 2010 .
[11] T. Friede,et al. A comparison of methods for adaptive sample size adjustment , 2001, Statistics in medicine.
[12] Heinz Schmidli,et al. Robustness of methods for blinded sample size re‐estimation with overdispersed count data , 2013, Statistics in medicine.
[13] T. Friede,et al. Re-calculating the sample size in internal pilot study designs with control of the type I error rate. , 2000, Statistics in medicine.
[14] B. Turnbull,et al. Group Sequential Methods with Applications to Clinical Trials , 1999 .
[15] Frank Miller,et al. Variance Estimation in Clinical Studies with Interim Sample Size Reestimation , 2005, Biometrics.
[16] Michael A Proschan,et al. Sample size re‐estimation in clinical trials , 2009, Biometrical journal. Biometrische Zeitschrift.
[17] Christian Confavreux,et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[18] Richard J Cook,et al. Two‐stage design of clinical trials involving recurrent events , 2009, Statistics in medicine.
[19] Richard Nicholas,et al. Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: A systematic review and meta-analysis , 2012, Multiple sclerosis.
[20] B. A. de Jong,et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis , 1836 .
[21] Michael A Proschan,et al. Two-Stage Sample Size Re-Estimation Based on a Nuisance Parameter: A Review , 2005, Journal of biopharmaceutical statistics.
[22] Meinhard Kieser,et al. Sample Size Recalculation in Internal Pilot Study Designs: A Review , 2006, Biometrical journal. Biometrische Zeitschrift.
[23] Meinhard Kieser,et al. Blinded sample size re‐estimation in superiority and noninferiority trials: bias versus variance in variance estimation , 2013, Pharmaceutical statistics.
[24] T Friede,et al. Blinded Sample Size Reestimation with Negative Binomial Counts in Superiority and Non-inferiority Trials , 2010, Methods of Information in Medicine.
[25] P. McCullagh,et al. Generalized Linear Models, 2nd Edn. , 1990 .
[26] K E Muller,et al. Controlling test size while gaining the benefits of an internal pilot design. , 2001, Biometrics.
[27] Liming Xiang,et al. Sensitivity of Test for Overdispersion in Poisson Regression , 2005, Biometrical journal. Biometrische Zeitschrift.